GYRE
Price
$9.12
Change
-$0.07 (-0.76%)
Updated
Apr 24 closing price
Capitalization
854.93M
13 days until earnings call
MIST
Price
$1.26
Change
+$0.10 (+8.62%)
Updated
Apr 24 closing price
Capitalization
67.23M
24 days until earnings call
Ad is loading...

GYRE vs MIST

Header iconGYRE vs MIST Comparison
Open Charts GYRE vs MISTBanner chart's image
Gyre Therapeutics
Price$9.12
Change-$0.07 (-0.76%)
Volume$109.53K
Capitalization854.93M
Milestone Pharmaceuticals
Price$1.26
Change+$0.10 (+8.62%)
Volume$1.97M
Capitalization67.23M
GYRE vs MIST Comparison Chart
Loading...
GYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MIST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GYRE vs. MIST commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GYRE is a StrongBuy and MIST is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (GYRE: $9.12 vs. MIST: $1.26)
Brand notoriety: GYRE and MIST are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GYRE: 63% vs. MIST: 66%
Market capitalization -- GYRE: $854.93M vs. MIST: $67.23M
GYRE [@Biotechnology] is valued at $854.93M. MIST’s [@Biotechnology] market capitalization is $67.23M. The market cap for tickers in the [@Biotechnology] industry ranges from $275.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.16B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GYRE’s FA Score shows that 0 FA rating(s) are green whileMIST’s FA Score has 0 green FA rating(s).

  • GYRE’s FA Score: 0 green, 5 red.
  • MIST’s FA Score: 0 green, 5 red.
According to our system of comparison, GYRE is a better buy in the long-term than MIST.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GYRE’s TA Score shows that 4 TA indicator(s) are bullish while MIST’s TA Score has 4 bullish TA indicator(s).

  • GYRE’s TA Score: 4 bullish, 4 bearish.
  • MIST’s TA Score: 4 bullish, 7 bearish.
According to our system of comparison, GYRE is a better buy in the short-term than MIST.

Price Growth

GYRE (@Biotechnology) experienced а +2.70% price change this week, while MIST (@Biotechnology) price change was +41.75% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.06%. For the same industry, the average monthly price growth was -5.30%, and the average quarterly price growth was -11.62%.

Reported Earning Dates

GYRE is expected to report earnings on Aug 19, 2025.

MIST is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+8.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GYRE($855M) has a higher market cap than MIST($67.2M). GYRE YTD gains are higher at: -24.628 vs. MIST (-46.610). GYRE has higher annual earnings (EBITDA): 11.8M vs. MIST (-37.83M). MIST has more cash in the bank: 69.7M vs. GYRE (25.1M). GYRE has less debt than MIST: GYRE (1.8M) vs MIST (54.8M). GYRE has higher revenues than MIST: GYRE (105M) vs MIST (0).
GYREMISTGYRE / MIST
Capitalization855M67.2M1,272%
EBITDA11.8M-37.83M-31%
Gain YTD-24.628-46.61053%
P/E Ratio182.40N/A-
Revenue105M0-
Total Cash25.1M69.7M36%
Total Debt1.8M54.8M3%
FUNDAMENTALS RATINGS
GYRE vs MIST: Fundamental Ratings
GYRE
MIST
OUTLOOK RATING
1..100
2317
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
61
Fair valued
PROFIT vs RISK RATING
1..100
78100
SMR RATING
1..100
9698
PRICE GROWTH RATING
1..100
7993
P/E GROWTH RATING
1..100
39100
SEASONALITY SCORE
1..100
n/a75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MIST's Valuation (61) in the Pharmaceuticals Major industry is in the same range as GYRE (89) in the null industry. This means that MIST’s stock grew similarly to GYRE’s over the last 12 months.

GYRE's Profit vs Risk Rating (78) in the null industry is in the same range as MIST (100) in the Pharmaceuticals Major industry. This means that GYRE’s stock grew similarly to MIST’s over the last 12 months.

GYRE's SMR Rating (96) in the null industry is in the same range as MIST (98) in the Pharmaceuticals Major industry. This means that GYRE’s stock grew similarly to MIST’s over the last 12 months.

GYRE's Price Growth Rating (79) in the null industry is in the same range as MIST (93) in the Pharmaceuticals Major industry. This means that GYRE’s stock grew similarly to MIST’s over the last 12 months.

GYRE's P/E Growth Rating (39) in the null industry is somewhat better than the same rating for MIST (100) in the Pharmaceuticals Major industry. This means that GYRE’s stock grew somewhat faster than MIST’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GYREMIST
RSI
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
83%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
84%
Momentum
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
76%
MACD
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
86%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 1 day ago
82%
Declines
ODDS (%)
Bearish Trend 25 days ago
82%
Bearish Trend 18 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
88%
View a ticker or compare two or three
Ad is loading...
GYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MIST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TYGO0.810.04
+5.47%
Tigo Energy
INTU614.8318.78
+3.15%
Intuit
RVMD38.581.14
+3.04%
Revolution Medicines
MCB60.811.34
+2.25%
Metropolitan Bank Holding Corp
CNXN61.550.93
+1.53%
PC Connection

GYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GYRE has been loosely correlated with SPRC. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if GYRE jumps, then SPRC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GYRE
1D Price
Change %
GYRE100%
-0.76%
SPRC - GYRE
38%
Loosely correlated
+1.71%
SRPT - GYRE
37%
Loosely correlated
+3.82%
BEAM - GYRE
36%
Loosely correlated
+1.51%
PYXS - GYRE
35%
Loosely correlated
+0.93%
RYTM - GYRE
35%
Loosely correlated
+5.23%
More

MIST and

Correlation & Price change

A.I.dvisor tells us that MIST and AKBA have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MIST and AKBA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MIST
1D Price
Change %
MIST100%
+8.62%
AKBA - MIST
33%
Poorly correlated
+5.56%
ETNB - MIST
31%
Poorly correlated
+4.23%
GYRE - MIST
29%
Poorly correlated
-0.76%
PRAX - MIST
29%
Poorly correlated
-1.61%
OSRH - MIST
29%
Poorly correlated
+0.73%
More